A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05155709
- Locations
- 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇹🇷Novartis Investigative Site, Izmir, Turkey
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Cullinan Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05143996
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 44
- Registration Number
- NCT05144243
- Locations
- 🇨🇳
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 233179, Beijing, Beijing, China
🇨🇳Peking University International Hospital /ID# 232254, Beijing, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center /ID# 231793, Guangzhou, Guangdong, China
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05100303
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- Conditions
- B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)Multiple MyelomaPlasma Cell LeukemiaHodgkin LymphomaT-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic LeukmeiaMyelodysplastic Syndrome / Chronic Myelomonocytic LeukemiaBlastic Transformation of Chronic Myeloid LeukemiaGerm Cell Tumors
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT05092451
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Conditions
- Acute Myeloid Leukaemia RefractoryMyelodysplastic SyndromesAcute Lymphocytic LeukaemiaBlastic Plasmacytoid Dendritic Cell Neoplasia
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 101
- Registration Number
- NCT05086315
- Locations
- 🇺🇸
Emory University School of Medicine- Grady Campus- Site Number : 8400006, Atlanta, Georgia, United States
🇺🇸Montefiore Hutchinson Campus- Site Number : 8400012, Bronx, New York, United States
🇺🇸City of Hope-Site Number:8400002, Duarte, California, United States
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Conditions
- LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05061147
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Pharmacokinetics, Tolerability and Safety of NEX-18a
- Conditions
- Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
- Interventions
- Drug: NEX-18a injection
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 2
- Registration Number
- NCT05048498
- Locations
- 🇸🇪
Karolinska University Hospital Huddinge, Huddinge, Sweden
🇸🇪Kliniska Forsknings och Utvecklings Enheten KFUE, Uppsala, Sweden
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
- Conditions
- Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05038800
- Locations
- 🇺🇸
Roswell Park Cancer Institute ( Site 0006), Buffalo, New York, United States
🇺🇸University of Texas MD Anderson Cancer Center ( Site 0004), Houston, Texas, United States
🇮🇱Hadassah Medical Center ( Site 0100), Jerusalem, Israel
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Kronos Bio
- Target Recruit Count
- 24
- Registration Number
- NCT05028751
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States